Free Trial

Which Healthcare Stock Is the Best Buy Right Now?

Modern medical technology system and devices - stock image

Key Points

  • Clinical-stage pharmaceuticals firm Viking Therapeutics has the potential to upend the GLP-1 agonist space with a new drug candidate.
  • Absci has seen significant success with its AI-driven drug creation platform, but it faces funding challenges.
  • Elevance's leadership in the health benefits space should help it weather any regulatory storms as it remains a strong defensive choice in the sector.
  • Five stocks we like better than Viking Therapeutics.
Remove Ads

In the world of upstart pharmaceuticals and healthcare companies, timing is everything. These firms often struggle for an extended period of time before becoming profitable, but when they see success with a new product—or even clinical trial results suggesting a new product could be on the horizon—they can experience huge rallies in a very short period of time.

While timing the market is typically a losing proposition for investors, there is something to be said for tracking firms that other investors are interested in. Investors exercising caution should beware of the risk of entering a position in a trending stock too late after it has already peaked.

With healthcare firms, this window can be incredibly small. Nonetheless, three such companies that have recently appeared frequently on MarketBeat reader watchlists include Viking Therapeutics Inc. NASDAQ: VKTX, Absci Corp. NASDAQ: ABSI, and Elevance Health Inc. NYSE: ELV.

Viking's VK2735: A Potential Game-Changer in the GLP-1 Weight Loss Market Amid Investor Uncertainty

Viking Therapeutics Stock Forecast Today

12-Month Stock Price Forecast:
$95.18
298.08% Upside
Buy
Based on 12 Analyst Ratings
Current Price$23.91
High Forecast$138.00
Average Forecast$95.18
Low Forecast$38.00
Viking Therapeutics Stock Forecast Details

Clinical-stage biopharma firm Viking has been at the top of many investors' minds because of recent headlines about its potential contribution to the red-hot GLP-1 agonist space. These drugs—the most prominent examples of which include Ozempic by Eli Lilly & Co. NYSE: LLY and Wegovy by Novo Nordisk A/S NYSE: NVO—have dominated the medical industry in recent months for their capacity to aid patients attempting to lose weight. Viking's VK2735, which completed enrollment for a Phase 2 clinical trial on March 26, could break up what is essentially a duopoly between the two much larger companies.

Remove Ads

Initial studies of Viking's drug candidate suggest that it may help patients achieve weight loss faster than some of the GLP-1 agonists already on the market. The company also may have an advantage over other GLP-1 drugs because it is developing VK2735 in both injectable and oral formulations, which should appeal to needle-averse customers.

On the other hand, investors have grown impatient as they wait for a Phase 3 trial on VK2735, with some suggesting that Viking has moved too slowly through the process. That's one reason why shares of VKTX are down more than 67% in the year leading to March 27, 2025. Investors optimistic about the longer-term prospects of VK2735 might find that the price drop offers an opportunity to buy the dip.

Absci's AI-Driven Drug Development Shows Promise, But Investors Eye Rising Losses and Cash Burn

Absci Stock Forecast Today

12-Month Stock Price Forecast:
$7.60
216.67% Upside
Buy
Based on 5 Analyst Ratings
Current Price$2.40
High Forecast$10.00
Average Forecast$7.60
Low Forecast$5.00
Absci Stock Forecast Details

Absci utilizes AI technology in its drug identification and creation process. The firm has recently noted some significant successes with its platform, including the announcement in December of its ABS-201 program for androgenic alopecia and promising pipeline candidates in the areas of inflammation treatment and immuno-oncology, among others.

As the company ramps up its drug development platform, investors won't be surprised to see that expenses—and net losses—have mounted. In the fourth quarter of 2024, for example, research and development costs climbed by roughly 50% year-over-year (YOY), contributing to net losses that widened to $29 million from $23.5 million a year prior.

Maintaining cash reserves until Absci builds its capacity to generate revenue will be essential. The company's cash and equivalent reserves dwindled to $112.4 million as of the end of 2024 from $127.1 million three months prior. On the plus side, though, Absci's gross use of cash and equivalents for the full year came in below external forecasts. Investors are optimistic that Absci can continue to moderate its spending while advancing its potential drug candidates, and they might find that its decline of 48% in the last year warrants a buy while shares are cheap.

Elevance: A Defensive Play in Healthcare With Strong Valuation and AI-Driven Growth Potential

Elevance Health Stock Forecast Today

12-Month Stock Price Forecast:
$519.81
20.04% Upside
Moderate Buy
Based on 17 Analyst Ratings
Current Price$433.02
High Forecast$649.00
Average Forecast$519.81
Low Forecast$440.00
Elevance Health Stock Forecast Details

As a major health benefits provider, Elevance is well-established and operates outside the pharmaceutical space, unlike the companies mentioned above. This makes it a defensive healthcare play that can help balance riskier investments for cautious investors.

Elevance has attractive value metrics, including a price-to-sales ratio of 0.55 and a comparably low forward price-to-earnings ratio of 12.7. As the company continues to integrate AI, it is likely to boost efficiency and margins.

And while there is widespread uncertainty about the impact of changing regulations on the health benefits industry, Elevance's strong position should allow it to withstand any challenges. Fourteen out of 16 analysts have rated it a Buy, with a consensus price target more than 21% above where shares are trading as of March 27, 2025.

Should You Invest $1,000 in Viking Therapeutics Right Now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Nathan Reiff
About The Author

Nathan Reiff

Contributing Author

Fundamental analysis, ETFs, Consumer Staples

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Viking Therapeutics (VKTX)
4.2247 of 5 stars
$23.91-1.0%N/A-23.91Buy$95.18
Eli Lilly and Company (LLY)
4.9471 of 5 stars
$803.70-2.7%0.75%68.63Moderate Buy$1,009.72
Novo Nordisk A/S (NVO)
4.8252 of 5 stars
$68.00-2.1%2.31%20.67Moderate Buy$145.25
Absci (ABSI)
2.4415 of 5 stars
$2.40-4.4%N/A-2.58Buy$7.60
Elevance Health (ELV)
4.6398 of 5 stars
$433.02-0.4%1.58%16.91Moderate Buy$519.81
Compare These Stocks  Add These Stocks to My Watchlist 

Remove Ads

Featured Articles and Offers

HIMS Stock Up 120%! More Growth Ahead?

HIMS Stock Up 120%! More Growth Ahead?

Hims & Hers (NYSE: HIMS) has skyrocketed 120% in just a month! Is it the next big disruptor in healthcare, or is it overpriced?

Recent Videos

 5 Stocks to BUY NOW in April 2025
3 Bank Stocks Defying Market Turmoil—Cheap Options Trades!
Time to Buy SoFi? Fintech’s Next Big Move

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads